Author Response: SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Affiliations

Comment

Adája E Baars et al. Neurology. 2023.

. 2023 Jul 4;101(1):51.

doi: 10.1212/WNL.0000000000207541.

No abstract available

Comment on

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
Baars AE, Kuitwaard K, de Koning LC, Luijten LWG, Kok WM, Eftimov F, Wieske L, Goedee HS, van der Pol WL, Blomkwist-Markens PH, Horemans AMC, Jacobs BC, van Doorn PA. Baars AE, et al. Neurology. 2023 Jan 10;100(2):e182-e191. doi: 10.1212/WNL.0000000000201376. Epub 2022 Sep 20. Neurology. 2023. PMID: 36127144
Reader Response: SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.
Harth CE. Harth CE. Neurology. 2023 Jul 4;101(1):50-51. doi: 10.1212/WNL.0000000000207542. Neurology. 2023. PMID: 37400257 Free PMC article. No abstract available.

1. Baars AE, Kuitwaard K, de Koning LC, et al. SARS-CoV-2 vaccination safety in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. Neurology. 2023;100(2):e182-e191. doi: 10.1212/WNL.0000000000201376 - DOI - PubMed
1. Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection [published correction appears in Nat Med. 2021;27(12):2249]. Nat Med. 2021;27(12):2144-2153. doi: 10.1038/s41591-021-01556-7 - DOI - PMC - PubMed